Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Volume today is just over 3m at present, certainly above usual average - but on the day of the original announcement it was nearer 17m. I personally don’t think this is actual news driven - just speculation and the herd is of course following - based on the affordability issues, if this is based on a likely Takeda deal, then I would be very surprised if this finished near the £37.55 at present and I can see a fall later after the profit taking... that said I’ve been wrong before! If there was another bidder in play then I could understand the sudden surge but not based on what we know so far and volumes. Let’s see... ATB, Scfc
There is currently about a $10bn difference in SPs beteeen the 2 current SPs (in Shire’s favour)...and that is.before any usual premium offer made on M&A deals. ATB, Scfc
It was tongue in cheek. That said, how do you think Takeda can afford a bid of £40+???
Bid below current sp not likely. Taked will offer 40+
If the share price goes up anymore then Takeda may end up bidding at a discount rather than a premium to the current SP! 😉
It was brief i must admit lol but it�s on the move again.
Red, i hear you about strong USD leading to higher SP for shire and most of ftse 100 companies in fact. But shire doesn't respond to usd change as it should do. On many occasions in the past usd has shot up causing most if not all stocks to jump 3 to 4%, but what did shire do? Dropped 2%. Something else is at play here today
I wouldn't describe 2% as flying upwards !
I think it was the surprisingly lower inflation number of 2.5% verses an expected 2.7%. This had an immediate impact on cable rate dropping a cent. Any strengthening in USD v GBP helps SHP share price due to earnings mostly in USD.
To be fair, didn’t someone seemingly know something last week when it had a similar move (but that time downwards)! All I can see from my feed is that it wasn’t an AT trade and less that 1/2 of today’s trades are AT trades which is unusual. Probably a big single buy that has been read as a signal by others, who knows? Scfc
Thanks, redtom. Scfc
I would love to know who knew what at about 11:25
Cant be Takeda. They will wait till the last second. I think there may another bidder approaching shire :-)
Hargreaves Landsdown. They're pretty good in my opinion. I recently moved a whole of stuff from Barclays for that reason.
Well done, that’s a good day trade Who is your broker? Mine seems to be not offering prices during the volatility...Scfc
Either way I'm out of the ones I bought earlier today. Lucky timing for me as I added 2500 at 36.10 earlier today. Just off loaded it at 37.02. Live to day-trade another day.
Rumour or facts the reaaon for a quick increase? Who knows...
???
Share price flying upwards as i speak any idea why?
Quote right, hope you got your spurs on this is a wiled mare. IMO hedging in both directions will make you profit, just a question of proportioning and time not so timing although it would make it perfection.
Notgreedy, Tak could ask for extension but I seriously doubt. If there is a bid, I totally agree that it will be rejected. But I just hope the details of it are made public knowledge. I would hate to read a Notification that merely says that Tak have walked away because they were rebuffed by Shire BoD. SP will yoyo heavily on any Tak announcement and I think it will yoyo significantly in both directions for quite a while after Tak have gone away. It does seem that Pharma M&A is back in favour for 2018 so there may be other approaches even if this falls flat on its face. As you say, this nag will give us one hell of a ride!
Red, Tak can ask for extension, can stop shp selling bits off buy making conditional offer for d whole co, whatever first offer for shp will be it will be rejected by shp bod, seriously undervalued co, then haggling might ensue. Whatever comes from Tak will cause initial violent sp reaction in one direction soon to be reversed in opposite. All this jmo..
Continued..... e professionals flexibility in treating von Willebrand disease with an appropriate dose of von Willebrand factor, with or without recombinant factor VIII, based on each patient's unique needs."1,5 The approval of VONVENDI in surgical settings was based on results from a Phase 3 prospective, open-label, multicenter trial to evaluate the efficacy and safety of VONVENDI with or without recombinant FVIII treatment in elective surgical procedures in adults (age 18 years and older) diagnosed with severe VWD.1 Results from the study showed VONVENDI met its primary endpoint, demonstrating overall hemostatic efficacy assessed 24 hours after the last perioperative VONVENDI infusion or at completion of study visit, whichever occurred earlier.1 The overall median dosing frequency of once-daily was demonstrated to normalize hemostasis in appropriate patients.1 One study participant developed deep vein thrombosis three days after undergoing hip replacement surgery while receiving VONVENDI.1 In addition to the expanded use of VONVENDI, the updated Prescribing Information includes new information about pharmacokinetics and storage of VONVENDI. VONVENDI can be stored at refrigerated temperature 2�C to 8�C (36�F to 46�F) or room temperature not to exceed 30�C (86�F). Do not freeze. Store VONVENDI in the original box and protect it from extreme exposure to light.
Shire plc : FDA APPROVES VONVENDI� FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE FDA APPROVES VONVENDI� [VON WILLEBRAND FACTOR (RECOMBINANT)] FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE1 Expanded use for VONVENDI - the first and only purified recombinant von Willebrand factor - builds on previously approved on-demand treatment indication1 VONVENDI now offers an individualized approach to bleed control in appropriate patients undergoing surgery1 von Willebrand disease is the most common inherited bleeding disorder, affecting up to one percent of the U.S. population2 Cambridge, Ma. - April 17, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare disease, today announced the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (recombinant)], a recombinant von Willebrand factor (rVWF) treatment for perioperative management of bleeding in adults (age 18 and older) with von Willebrand disease (VWD).1 VONVENDI is also indicated for on-demand treatment and control of bleeding episodes, and it is the first and only recombinant treatment for adults living with VWD, the most common inherited bleeding disorder.1,3-4 "The expanded approval of VONVENDI represents a new treatment option for the surgical setting that can be tailored to each patient's individual needs,"1,3-5 said Andreas Busch, Global Head of Research and Development, Shire. "It's an important milestone in support of our vision of personalizing treatment and helping to address unmet needs for people with bleeding disorders."1,3-5 People with VWD lack proper quantities of VWF or functioning VWF, and they may or may not have a secondary factor VIII (FVIII) deficiency.5 Since not every person with VWD or every bleed requires FVIII replacement, VONVENDI allows healthcare providers to dose recombinant VWF independent of recombinant FVIII based on clinical judgement for each patient, taking into account severity, site of bleeding, the patient's medical history and monitoring of appropriate clinical and laboratory measures.1 Independent dosing with VONVENDI offers an individualized approach to bleed control in appropriate patients undergoing surgery.1 "Persons with von Willebrand disease face a heightened risk of bleeding during surgery and may require factor treatment before, during or after surgery," said Michael Tarantino, M.D., Professor of Pediatrics and Medicine, University of Illinois College of Medicine, and Medical Director and President, The Bleeding and Clotting Disorders Institute. "For surgeries requiring repeated, frequent infusions with combined von Willebrand factor and factor VIII concentrates, an excessive rise in factor VIII levels may increase the risk of thromboembolic complications, such as blood clots.1,7 The expanded use for VONVENDI in surgical settings gives healthcar
I agree any announcement will be late. But we only have a week left anyhow. I would guess after the weekend so I'll go for Tuesday 24th as not taken yet!. It's quite possible that something could be leaked to the press over the weekend followed up by a formal announcement on Monday morning. I'm still of the opinion (say 60:40) that no bid will be made by Takeda. I think they will make their excuses (they have plenty of options) and back down. I would love to be wrong. Even a low ball offer (�37 - 40) would be great as it would really alert the market. Given there seems to be a lot of M&A in the pharma industry this year (after next to none last year), any offer is bound to get others thinking. A rival bid would then put us into the acceptable territory range (�40-45). But most of this is wishful thinking on my part.